EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020

Aina Harimanana, Dina Ny Aina Liantsoa Randriamiarinjatovo, Tovonanahary Angelo Rakotomanga, Judickaelle Irinantenaina, Leah F Moriarty, Veronica Laird, Dhruviben Patel, Rispah A Abdallah, Zhou Zhiyong, Samaly Souza Svigel, Laurent Kapesa, Jocelyn Razafindrakoto und 6 weitere

The American Journal of Tropical Medicine and Hygiene · 2026

DOI: 10.4269/ajtmh.24-0844 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2026. Verfasst von Aina Harimanana und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur de Madagascar, Antananarivo, Madagascar. Hauptthemen laut MEDLINE: Malaria, Falciparum, Amodiaquine, Antimalarials, Artemisinins. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of artesunate + amodiaquine (ASAQ) and artemether + lumefantrine (AL) for treating malaria was investigated in Madagascar in 2020. A randomized parallel-group study was conducted at four health centers (Antsenavolo, Vohitromby, and Matanga in the southeastern region and Ankazomborona in the northwestern region). The therapeutic efficacy and safety of ASAQ and AL were assessed using the WHO protocol, with a 28-day follow-up period. Children aged 6 months to 14 years with uncomplicated Plasmodium falciparum ( P. falciparum ) malaria were randomly assigned to receive either ASAQ or AL. Genotyping assays for the pfK13 gene were conducted on P. falciparum isolates obtained from dry blood samples collected on Day 0. Of 765 enrolled patients, 709 (92.7%) reached the study endpoint. Among the per-protocol population, crude adequate clinical and parasitological response (ACPR) rates were 99%, 99%, 100%, and 100% for Antsenavolo, Vohitromby, Matanga, and Ankazomborona, respectively, in the ASAQ group and 98%, 91%, 90%, and 100% for the same locations, respectively, in the AL group. Polymerase chain reaction-corrected ACPR rates were 100% for the ASAQ group at all study sites, whereas for the AL group, they were 98.8% in Antsenavolo, 97.6% in Vohitromby, 100% in Matanga, and 100% in Ankazomborona. Day 3 slide positivity rates were 0%, 1%, 1%, and 0% for Antsenavolo, Vohitromby, Matanga, and Ankazomborona, respectively. During follow-up, mild and moderate adverse events, including gastrointestinal issues (abdominal pain and vomiting) and headache, were reported in 10.2% (72/709) of patients. Of 727 samples successfully analyzed for pfK13 , no mutation associated with artemisinin resistance was observed. The study results reveal that ASAQ and AL remain safe and efficacious for treating uncomplicated P. falciparum malaria in Madagascar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, FalciparumAmodiaquineAntimalarialsArtemisininsArtemether, Lumefantrine Drug CombinationArtesunateHumansMadagascarChild, PreschoolChildMaleFemaleAdolescentInfantPlasmodium falciparumDrug CombinationsTreatment OutcomeLumefantrine

Substanzen

AmodiaquineAntimalarialsArtemisininsamodiaquine, artesunate drug combinationArtemether, Lumefantrine Drug CombinationDrug CombinationsArtesunateLumefantrine

Autor:innen und Institutionen

  • Institut Pasteur de Madagascar, Antananarivo, Madagascar.
  • Programme National de Lutte Contre le Paludisme, Ministère de la Santé Publique de Madagascar, Antananarivo, Madagascar.
  • US President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
  • Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • US President's Malaria Initiative, US Agency for International Development, Antananarivo, Madagascar.

Zitieren

APA

Harimanana, A., Randriamiarinjatovo, D. N. A. L., Rakotomanga, T. A., Irinantenaina, J., Moriarty, L. F., Laird, V., Patel, D., Abdallah, R. A., Zhiyong, Z., Svigel, S. S., Kapesa, L., Razafindrakoto, J., Ralinoro, F., Rason, M. A., Andriamananjara, M. N., Razanatsiorimalala, S., Razafinjato, C., & Randrianarivelojosia, M. (2026). Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0844

Vancouver

Harimanana A, Randriamiarinjatovo DNAL, Rakotomanga TA, Irinantenaina J, Moriarty LF, Laird V, et al. Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020. The American Journal of Tropical Medicine and Hygiene. 2026. doi:10.4269/ajtmh.24-0844

BibTeX
@article{Harimanana2026,
  author = {Harimanana, Aina and Randriamiarinjatovo, Dina Ny Aina Liantsoa and Rakotomanga, Tovonanahary Angelo and Irinantenaina, Judickaelle and Moriarty, Leah F and Laird, Veronica and Patel, Dhruviben and Abdallah, Rispah A and Zhiyong, Zhou and Svigel, Samaly Souza and Kapesa, Laurent and Razafindrakoto, Jocelyn and Ralinoro, Fanomezantsoa and Rason, Marie Ange and Andriamananjara, Mauricette Nambinisoa and Razanatsiorimalala, Seheno and Razafinjato, Celestin and Randrianarivelojosia, Milijaona},
  title = {Efficacy and Safety of Artesunate + Amodiaquine and Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Madagascar, 2020},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2026},
  doi = {10.4269/ajtmh.24-0844}
}
Kostenlos starten →